|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
SE8804164A0
(sv)
|
1988-11-17 |
1990-05-18 |
Per Prisell |
Farmaceutisk beredning
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5177197A
(en)
|
1990-02-27 |
1993-01-05 |
Ludwig Institute For Cancer Research |
Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
|
|
US5229495A
(en)
|
1991-06-18 |
1993-07-20 |
Ludwig Institute For Cancer Research |
Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
ES2149823T3
(es)
|
1992-09-03 |
2000-11-16 |
Univ California |
Factor y composiciones que afectan al tejido dorsal.
|
|
US5453492A
(en)
|
1993-07-28 |
1995-09-26 |
La Jolla Cancer Research Foundation |
60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
|
|
AU2404695A
(en)
|
1994-05-04 |
1995-11-29 |
Mount Sinai Hospital Corporation |
Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
|
|
US5616561A
(en)
|
1995-03-31 |
1997-04-01 |
Regents Of The University Of California |
TGF-β antagonists as mitigators of radiation-induced tissue damage
|
|
US6610510B1
(en)
|
1997-04-29 |
2003-08-26 |
Regeneron Pharmaceuticals, Inc. |
Morphogenic proteins
|
|
AU7608898A
(en)
|
1997-06-06 |
1998-12-21 |
Regeneron Pharmaceuticals, Inc. |
Ntn-2 member of tnf ligand family
|
|
US5935852A
(en)
|
1997-07-03 |
1999-08-10 |
Genetics Institute, Inc. |
DNA molecules encoding mammalian cerberus-like proteins
|
|
WO1999061044A1
(en)
|
1998-05-28 |
1999-12-02 |
The Board Of Trustees Of The University Of Arkansas |
Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
|
|
WO2000022909A2
(en)
|
1998-10-19 |
2000-04-27 |
Biotech Australia Pty. Limited |
Systems for oral delivery
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
ATE481487T1
(de)
|
1998-11-27 |
2010-10-15 |
Ucb Sa |
Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
|
|
WO2000055193A2
(en)
|
1999-03-12 |
2000-09-21 |
Regeneron Pharmaceuticals, Inc. |
Human dan/cerberus related protein 6 (dcr6)
|
|
US7358056B1
(en)
|
1999-08-30 |
2008-04-15 |
Signal Pharmaceuticals |
Methods for modulating signal transduction mediated by TGF-β and related proteins
|
|
WO2001047944A2
(en)
|
1999-12-28 |
2001-07-05 |
Curagen Corporation |
Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
|
|
US20020168638A1
(en)
|
2000-01-24 |
2002-11-14 |
Robert Schlegel |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
|
|
AU2001229508A1
(en)
|
2000-01-31 |
2001-08-07 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
AU3087801A
(en)
|
2000-02-04 |
2001-08-14 |
Molecular Dynamics Inc |
Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
|
|
WO2001088103A2
(en)
|
2000-05-12 |
2001-11-22 |
University Of Utah Research Foundation |
Compositions and methods for tissue dedifferentiation and regeneration
|
|
US20040087016A1
(en)
|
2000-05-12 |
2004-05-06 |
University Of Utah Research Foundation |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
JP2003534813A
(ja)
|
2000-06-01 |
2003-11-25 |
アムジェン インコーポレーテッド |
シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用
|
|
EP1366156A2
(en)
|
2000-06-19 |
2003-12-03 |
F. Hoffmann-La Roche Ag |
Osteolevin gene polymorphisms
|
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
|
WO2002054940A2
(en)
|
2001-01-12 |
2002-07-18 |
University Of Medicine & Dentistry Of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
|
US20040235728A1
(en)
|
2001-11-08 |
2004-11-25 |
Stoch Selwyn Aubrey |
Compositions and methods for treating osteoporosis
|
|
AU2002366951A1
(en)
|
2001-12-10 |
2003-07-09 |
Nuvelo,Inc. |
Novel nucleic acids and polypeptides
|
|
GB0130738D0
(en)
|
2001-12-21 |
2002-02-06 |
Serono Internat S A |
Protein
|
|
GB2385052A
(en)
|
2002-02-05 |
2003-08-13 |
Leuven K U Res & Dev |
Treatment of spondyloarthropathies
|
|
US20030186915A1
(en)
|
2002-02-11 |
2003-10-02 |
Yang Pan |
Regulatory polynucleotides and uses thereof
|
|
JP2005253301A
(ja)
|
2002-02-20 |
2005-09-22 |
Taisho Pharmaceut Co Ltd |
骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
|
|
AU2003223214B2
(en)
|
2002-03-01 |
2008-09-18 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
|
TWI282283B
(en)
|
2002-05-17 |
2007-06-11 |
Wyeth Corp |
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
|
|
US20040023356A1
(en)
|
2002-06-14 |
2004-02-05 |
Robb Krumlauf |
Wise/Sost nucleic acid sequences and amino acid sequences
|
|
US7622592B2
(en)
|
2002-11-01 |
2009-11-24 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
|
WO2004062621A2
(en)
|
2003-01-13 |
2004-07-29 |
Georgia Tech Research Corporation |
Anti-inflammatory agents and methods of their use
|
|
MXPA05009805A
(es)
|
2003-03-14 |
2006-04-18 |
Celltech R & D Inc |
Ligandos para proteinas de enlace tgf-beta y usos de los mismos.
|
|
CA2524409C
(en)
|
2003-05-07 |
2011-12-20 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
CA2529623A1
(en)
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
WO2005023311A2
(en)
|
2003-09-11 |
2005-03-17 |
Association Francaise Retinitis Pigmentosa (Afrp) |
Novel targets for the treatment of retina diseases
|
|
US8461155B2
(en)
|
2003-09-22 |
2013-06-11 |
University Of Connecticut |
Sclerostin and the inhibition of WNT signaling and bone formation
|
|
US20080249038A1
(en)
|
2003-10-07 |
2008-10-09 |
Quark Biotech, Inc. |
Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
|
|
CA2566746A1
(en)
|
2004-05-14 |
2005-12-01 |
Baylor College Of Medicine |
Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
|
|
AU2005250441A1
(en)
|
2004-05-27 |
2005-12-15 |
Acceleron Pharma Inc. |
TGF derepressors and uses related thereto
|
|
AU2006223579A1
(en)
|
2005-03-11 |
2006-09-21 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US20060293667A1
(en)
|
2005-05-19 |
2006-12-28 |
Agnes Vignery |
Bone implant device and methods of using same
|
|
WO2006135734A2
(en)
|
2005-06-10 |
2006-12-21 |
The Regents Of The University Of California |
Compositions and methods for altering bone density and bone patterning
|
|
EP1981910B1
(en)
|
2006-01-13 |
2013-06-26 |
A Chan Holding B.V. |
Method for identifying inhibitor of the glypican-sclerostin interaction
|
|
EP2423226A3
(en)
|
2006-11-10 |
2012-05-30 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
EP2460828A3
(en)
|
2006-11-10 |
2012-08-08 |
UCB Pharma, S.A. |
Antibodies and diagnostics
|
|
EP3345607B1
(en)
|
2006-12-29 |
2022-10-26 |
Ossifi-Mab LLC |
Methods of altering bone growth by administration of sost or wise antagonist or agonist
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
CN101896201A
(zh)
|
2007-12-14 |
2010-11-24 |
安进公司 |
使用抗硬骨素抗体治疗骨折的方法
|
|
AR075715A1
(es)
*
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
|
WO2010115932A1
(en)
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
US9617323B2
(en)
|
2010-06-07 |
2017-04-11 |
Joshua Rabbani |
Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
|
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
|
AP3981A
(en)
|
2011-03-25 |
2017-01-05 |
Amgen Inc |
Anti - sclerostin antibody crystals and formulations thereof
|
|
US20140127192A1
(en)
|
2011-04-19 |
2014-05-08 |
Amgen Inc |
Method for treating osteoporosis
|
|
SI2739311T1
(en)
|
2011-08-04 |
2018-07-31 |
Amgen Inc. |
Method for the treatment of bone defect defects
|
|
EP3712168A3
(en)
|
2011-12-28 |
2020-10-14 |
Amgen Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
|
AU2013285488B2
(en)
|
2012-07-05 |
2018-03-22 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
DK3334747T5
(da)
|
2015-08-13 |
2024-10-07 |
Amgen Inc |
Ladet dybdefiltrering af antigenbindende proteiner
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
KR20190037261A
(ko)
|
2016-08-08 |
2019-04-05 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
|
|
US10961305B2
(en)
*
|
2016-12-21 |
2021-03-30 |
Mereo Biopharma 3 Limited |
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
|
|
MX2019007161A
(es)
|
2016-12-21 |
2020-02-12 |
Mereo Biopharma 3 Ltd |
Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
CN109952093B
(zh)
|
2017-07-27 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
一种sost抗体药物组合物及其用途
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
EP3774879B1
(en)
|
2018-03-30 |
2026-01-28 |
Amgen Inc. |
C-terminal antibody variants
|
|
MA53272A
(fr)
|
2018-08-10 |
2021-11-17 |
Amgen Inc |
Procédé de préparation d'une formulation pharmaceutique d'anticorps
|